Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)Defense World · Oct 6, 2026
Talphera (TLPH) Upgraded to Buy: Here's What You Should KnowZacks Investment Research · Sep 21, 2026
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 3, 2026
Talphera, Inc. (TLPH) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire · Aug 12, 2026
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026PRNewsWire · Aug 5, 2026Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.06 | -$0.06 | Beat |
| May 13, 2026 | -$0.07 | -$0.04 | Beat |
| Mar 23, 2026 | -$0.08 | -$0.06 | Beat |
| Nov 12, 2025 | -$0.08 | -$0.11 | Miss |
| Aug 14, 2025 | -$0.12 | -$0.10 | Beat |
| May 14, 2025 | -$0.17 | -$0.10 | Beat |